1
|
Ma K, He Q, Dou Z, Hou X, Li X, Zhao J, Rao C, Feng Z, Sun K, Chen X, He Y, Zhang H, Li S. Current treatment outcomes of congenital heart disease and future perspectives. THE LANCET. CHILD & ADOLESCENT HEALTH 2023; 7:490-501. [PMID: 37301213 DOI: 10.1016/s2352-4642(23)00076-7] [Citation(s) in RCA: 13] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/13/2022] [Revised: 03/04/2023] [Accepted: 03/09/2023] [Indexed: 06/12/2023]
Abstract
China has the largest number of individuals with congenital heart disease (CHD) in the world and a heavy burden of CHD. Therefore, understanding current CHD treatment outcomes and patterns in China will contribute to global progress in CHD treatment and be a valuable experience. Generally, CHD treatment in China has satisfactory outcomes owing to the joint efforts by all relevant stakeholders across the country. However, efforts are needed to overcome the remaining challenges: management of mitral valve disease and paediatric end-stage heart failure needs to be improved; cohesive paediatric cardiology teams should be established and collaboration between hospitals enhanced; CHD-related medical resources need to be more accessible and equitable; and nationwide CHD databases should be enhanced. In the second paper of this Series, we aim to systematically summarise the current CHD treatment outcomes in China, discuss potential solutions, and provide future perspectives.
Collapse
Affiliation(s)
- Kai Ma
- Pediatric Cardiac Surgery Center, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
| | - Qiyu He
- Pediatric Cardiac Surgery Center, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China; State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
| | - Zheng Dou
- Pediatric Cardiac Surgery Center, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China; State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
| | - Xiaotong Hou
- Surgical Intensive Care Unit, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
| | - Xi Li
- National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
| | - Ju Zhao
- Surgical Intensive Care Unit, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
| | - Chenfei Rao
- Pediatric Cardiac Surgery Center, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
| | - Zicong Feng
- Department of Cardiac Surgery, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
| | - Kun Sun
- Department of Pediatric Cardiology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Xinxin Chen
- Cardiovascular Center, Guangzhou Women and Children's Medical Center, Guangzhou, China
| | - Yihua He
- Maternal-Fetal Medicine Centre in Fetal Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; Beijing Key Laboratory of Maternal-Fetal Medicine in Fetal Heart Disease, Beijing, China; Beijing Laboratory for Cardiovascular Precision Medicine, Beijing, China
| | - Hao Zhang
- Heart Center and Shanghai Institute of Pediatric Congenital Heart Disease and Shanghai Clinical Research Center for Rare Pediatric Diseases, Shanghai Children's Medical Center, National Children's Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Shoujun Li
- Pediatric Cardiac Surgery Center, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China; State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
| |
Collapse
|
2
|
Sun J, Yuan Y, Song Y, Hu Y, Bai X, Chen J, Zhong Q. Early results of totally endoscopic robotic aortic valve replacement: analysis of 4 cases. J Cardiothorac Surg 2022; 17:155. [PMID: 35698140 PMCID: PMC9195332 DOI: 10.1186/s13019-022-01899-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2021] [Accepted: 05/28/2022] [Indexed: 11/10/2022] Open
Abstract
Objective To evaluate the role of totally endoscopic robotic aortic valve replacement in cardiac surgery. Methods Four cases of totally robotic aortic valve replacement (AVR) were conducted from December 2016 to July 2018. All operations were completed with the Da Vinci robot Si™ system (intuitive Surgical, Inc. Sunnyvale, C.A, USA). Patients were male, with a mean age of 42.8 ± 6.2 years (range 32–49). Results AVR was completed with the Da Vinci Si™ system (intuitive Surgical, Inc. Sunnyvale, CA, USA). There was no mortality and no procedure-related morbidity. The mean cardiopulmonary bypass and mean cross-clamp time was 252 ± 13.6 min and 178.8 ± 17.1 min, respectively. The mean ICU time was 78.8 ± 27.1 h, and the mean hospital stay was 15 ± 3.5 d. During a mean follow-up of 3 years and 6 months, the patients returned to normal function, and no heart murmur was found. Compared with the operation, the body image score of the four patients increased after the operation, and the hospital anxiety and depression scale scores decreased, indicating that the patient's condition had been alleviated to a certain extent. Conclusion Totally endoscopic robotic AVR is a feasible and viable choice for patients but requires further improvement for broader use. Supplementary Information The online version contains supplementary material available at 10.1186/s13019-022-01899-3.
Collapse
Affiliation(s)
- Jiaqi Sun
- Department of Cardiovascular Surgery, Daping Hospital, Yuzhong District, Chongqing, China
| | - Ye Yuan
- Department of Cardiovascular Surgery, Daping Hospital, Yuzhong District, Chongqing, China
| | - Yi Song
- Department of Cardiovascular Surgery, Daping Hospital, Yuzhong District, Chongqing, China
| | - Yijie Hu
- Department of Cardiovascular Surgery, Daping Hospital, Yuzhong District, Chongqing, China
| | - Xue Bai
- Department of Cardiovascular Surgery, Daping Hospital, Yuzhong District, Chongqing, China
| | - Jing Chen
- Department of Cardiovascular Surgery, Daping Hospital, Yuzhong District, Chongqing, China
| | - Qianjin Zhong
- Department of Cardiovascular Surgery, Daping Hospital, Yuzhong District, Chongqing, China.
| |
Collapse
|